Last reviewed · How we verify
Nandrolone Decanoate (NANDROLONE DECANOATE)
Nandrolone Decanoate is an androgen medication originally developed by ASPEN GLOBAL INC and currently owned by Woodward Specl. It targets sex hormone-binding globulin and is used to treat anemia in chronic kidney disease. The drug is classified as a small molecule and was FDA-approved in 1962. Nandrolone Decanoate is available as a generic medication, with four generic manufacturers, and is off-patent. As an androgen, it plays a crucial role in the development and maintenance of male reproductive tissues and secondary sexual characteristics.
At a glance
| Generic name | NANDROLONE DECANOATE |
|---|---|
| Sponsor | Woodward Specl |
| Drug class | Androgen |
| Target | Sex hormone-binding globulin |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1962 |
Approved indications
- Anemia in chronic kidney disease
Common side effects
- Acne
- Hirsutism
- Male pattern baldness
- Deepening of voice in women
- Gynecomastia
- Edema
- Nausea
- Vomiting
- Diarrhea
- Insomnia
- Depression
- Excitation
Serious adverse events
- Hepatocellular neoplasms
- Peliosis hepatis
- Chronic priapism
- Testicular function inhibition
- Premature closure of epiphyses
- Decreased glucose tolerance
- Bleeding on concomitant anticoagulant therapy
- Epididymitis
- Bladder irritability
- Retention of serum electrolytes
Key clinical trials
- Peri-Operative Testosterone Administration in Primary Hip Arthroscopy (PHASE4)
- Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty (PHASE4)
- Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet (PHASE2)
- Nandrolone Decanoate in the Treatment of Telomeropathies (PHASE1,PHASE2)
- Assessment of Mechanisms of Improved Wound Healing (PHASE2,PHASE3)
- Anabolic Steroid and Propranolol in Paediatric Burn (NA)
- A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss (PHASE1)
- Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nandrolone Decanoate CI brief — competitive landscape report
- Nandrolone Decanoate updates RSS · CI watch RSS
- Woodward Specl portfolio CI